Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease | Zendy

Oliver A. Cornely | Zendy; Michael Robertson | Zendy; Shariq Haider | Zendy; Andrew Grigg | Zendy; Michelle Geddes | Zendy; Mickaël Aoun | Zendy; Werner Heinz | Zendy; Issam Raad | Zendy; Urs Schanz | Zendy; Ralf G. Meyer | Zendy; Sarah P. Hammond | Zendy; Kathleen M. Mullane | Zendy; Helmut Ostermann | Zendy; Andrew J. Ullmann | Zendy; Stefan Zimmerli | Zendy; Marlou L. P. S. van Iersel | Zendy; Deborah A Hepler | Zendy; Hetty Waskin | Zendy; Nicholas A. Kartsonis | Zendy; Johan Maertens | Zendy

Open Access

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease

Author(s) -

Oliver A. Cornely,

Michael Robertson,

Shariq Haider,

Andrew Grigg,

Michelle Geddes,

Mickaël Aoun,

Werner Heinz,

Issam Raad,

Urs Schanz,

Ralf G. Meyer,

Sarah P. Hammond,

Kathleen M. Mullane,

Helmut Ostermann,

Andrew J. Ullmann,

Stefan Zimmerli,

Marlou L. P. S. van Iersel,

Deborah A Hepler,

Hetty Waskin,

Nicholas A. Kartsonis,

Johan Maertens

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx263

Subject(s) - posaconazole , pharmacokinetics , medicine , open label , pharmacology , adverse effect , antifungal , amphotericin b , dermatology

A two-part (Phase 1B/3), sequential, open-label, multicentre study evaluated the pharmacokinetics (PK) and safety of intravenous (iv) posaconazole given as antifungal prophylaxis to neutropenic patients with AML or myelodysplastic syndrome (MDS) or to recipients at risk of invasive fungal disease (IFD) after allogeneic HSCT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research